DEX treatment of PDX-derived patient cells showed that DNMT3A-mutant–like samples were highly sensitive to the drug in the presence of RUX, comparable with cells from patients with DNMT3A-mutant T-ALL (Figure 6E). Here, DNMT3A is linked to acute lymphoblastic leukemia.